secwatch / observer
8-K filed March 10, 2026, 7:59 PM ET ticker NATR CIK 0000275053
earnings confidence high sentiment positive materiality 0.80

Nature's Sunshine Q4 net sales up 4.7% to $123.8M; EPS $0.23 vs ($0.02) YoY

NATURES SUNSHINE PRODUCTS INC

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NATURES SUNSHINE PRODUCTS INC reported the full year ended December 31, 2025 results: revenue $480.1 million, net income $19.5 million, EPS $1.06 per diluted share.

Period
the full year ended December 31, 2025
Revenue
$480.1 million
Net income
$19.5 million
EPS
$1.06 per diluted share
Result
reported results
Exact text from the filing
Net sales were up 5.7% to $480.1 million compared to $454.4 million (up 5.3% in constant currency). • GAAP net income attributable to common shareholders of $19.5 million, or $1.06 per diluted share, compared to $7.7 million, or $0.40 per diluted share.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NATURES SUNSHINE PRODUCTS INC reported the fourth quarter ended December 31, 2025 results: revenue $123.8 million, net income $4.1 million, EPS $0.23 per diluted share.

Period
the fourth quarter ended December 31, 2025
Revenue
$123.8 million
Net income
$4.1 million
EPS
$0.23 per diluted share
Result
reported results
Exact text from the filing
Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency). • GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.
View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NATURES SUNSHINE PRODUCTS INC filing history →

Source: SEC EDGAR
accession 0001628280-26-016535
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.